Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium – BioSpace

SALT LAKE CITY, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that multiple studies will be presented at the 2019 San Antonio Breast Cancer Symposium (SABCS) being held Dec. 10-14, 2019 in San Antonio, Tx.

"We are excited to present new data from several studies at SABCS this year, said Nicole Lambert, president of Myriad Oncology. "Our data represents Myriads commitment to advancing precision oncology for people with breast cancer and improving outcomes.

A list of the companys presentations at SABCS is below. Please visit Myriad at booth #113 to learn more about our portfolio of genetic tests for breast cancer. Follow Myriad on Twitter via @myriadgenetics and keep up to date with Symposium news by using the hashtag #SABCS19.

About Myriad myRisk Hereditary CancerThe Myriad myRisk Hereditary Cancer test uses an extensive number of sophisticated technologies and proprietary algorithms to evaluate 35 clinically significant genes associated with eight hereditary cancer sites including: breast, colon, ovarian, endometrial, pancreatic, prostate and gastric cancers and melanoma.

About riskScoreriskScore is a new clinically validated personalized medicine tool that enhances Myriads myRisk Hereditary Cancer test. riskScore helps to further predict a womens lifetime risk of developing breast cancer using clinical risk factors and genetic-markers throughout the genome. The test incorporates data from greater than 80 single nucleotide polymorphisms identified through 20 years of genome wide association studies in breast cancer and was validated in our laboratory to predict breast cancer risk in women of European descent. This data is then combined with a best-in-class family and personal history algorithm, the Tyrer-Cuzick model, to provide every patient with individualized breast cancer risk.

About EndoPredictEndoPredict is a second-generation, prognostic test that aids personalized treatment planning for patients with early-stage breast cancer. EndoPredict has been validated in over 3500 patients with node-negative and node-positive disease and is the leading breast prognostic in Europe. In contrast to first-generation multigene prognostic tests, EndoPredict incorporates a 12-gene molecular score with known prognostic factors tumor size and nodal status. In clinical studies, EndoPredict demonstrated its robust ability to predict recurrence risk across multiple time-periods: 0-5, 5-10, and 5-15 years. EndoPredict provides clinically actionable information to physicians and patients as they consider the use of adjuvant chemotherapy and extended endocrine therapy.

About Myriad GeneticsMyriad Genetics Inc. is a leading precision medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five critical success factors: building upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the Companys data across multiple genetic tests being featured at the 2019 San Antonio Breast Cancer Symposium being held Dec. 10-14, 2019 in San Antonio, Tx.; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

More:
Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium - BioSpace

‘Grey’s Anatomy’ Fans Are Pointing Out 1 Major Reason Bailey Is a Total Hypocrite – Showbiz Cheat Sheet

Season 16 of Greys Anatomy has largely focused on Meredith Greys fight to keep her medical license after committing insurance fraud. She made a poor judgment call and has been forced to face the consequences.

The story has gone this far because Miranda Bailey chose to turn in her head of general surgery, and fire those who supported her in her actions. Now, fans on Reddit are calling out Baileys actions, calling her a hypocrite. What happened? Lets take a look.

Late in season 15, Meredith met Gabby Rivera. Gabby came to the hospital complaining of stomach pain. When the young girl first came to the hospital, her father took her to the free clinic because she lacked health insurance. Immediately, it was apparent that the young girl needed more care than the free clinic could provide.

The doctors were sympathetic and Meredith instantly bonded with Gabby. The doctors helped Gabbys father apply for state coverage. When his request was denied because he made too much, Meredith immediately stepped up saying that she had it covered.

As the doctors prepared Gabby for surgery, Alex and Andrew DeLuca, who had also been treating the young girl, questioned Merediths plan. When Dr. Webber entered the scrub room asking why Merediths daughter was in surgery, it was clear. Meredith used her own insurance to cover the girl.

The surgery was a success, but the chief found out. DeLuca initially took the fall, protecting Meredith from jail. But ultimately, the truth was revealed and Meredith, Alex, and Richard lost their jobs.

Over the years we have seen the doctors push the boundaries and toe the line of whats ethical and whats not. Who could forget the infamous LVAD incident or when Meredith interfered with the Alzheimers trial? But there is one particular incident that has Reddit users calling out chief Miranda Bailey.

During Season 5, three women and their husbands were admitted to the hospital after their limo crashed during an ice storm. The episode was filled with emotion, betrayal, and infidelity. But at the heart, one of the women was worried about the insurance she was going to lose the next day.

Bailey was aware of this issue as the husband was rolled into the ER late that night. As the surgery began, Bailey confronted Alex about the time. Though the clock clearly read 2:30 a.m., Bailey insisted it was wrong. She wanted the clock turned back to 11:58 p.m. so the insurance company would have the right time.

Baileys actions were an obvious act of insurance fraud. She knew the man had no insurance and she bent the rules. But when Meredith did the same, her acts were unforgivable.

The storyline came to a conclusion during episode 8 of season 16. In an emotional hearing that involved Meredith confronting the man that killed her husband, every mistake Meredith had made was brought up. Her fellow doctors were left to defend her when faced with facts about her questionable actions.

When Miranda Bailey took the stand, she was flippant, acting as if she wanted Meredith to lose her license. When Richard later confronted Bailey about her actions, she admitted that she had felt betrayed. She lost her hospital, her best friend, and her best surgeons, all because no one came to her.

But had they betrayed her? Richard admitted he didnt tell her because he was protecting her. He didnt want her to lose her job in the fallout of it all. He protected Meredith because he knew Meredith would protect him. And he protected Bailey, because up until recently, he thought she would do the same.

When Bailey was faced with the facts, she had no other choice. She herself had done what she accused the other doctors of doing. She betrayed those closest to her.In the end, she stood up for Meredith and helped her retain her license something everyone expected her to do all along.

More here:
'Grey's Anatomy' Fans Are Pointing Out 1 Major Reason Bailey Is a Total Hypocrite - Showbiz Cheat Sheet

‘Grey’s Anatomy’: Fans Are Still Furious over the Death of This One CharacterThey Claim It Was Worse Than Losing McDreamy – Showbiz Cheat Sheet

There is a lot of heartache on ABCs Greys Anatomy. Fans were torn to pieces whenMerediths(Ellen Pompeo) husband, Derek Shepherd (Patrick Dempsey), tragically died.

Viewers will also never forget the surprising death of Izzie Stevens (Katherine Heigl) love interest, Denny Duquette (Jeffrey Dean Morgan). However, there is one death that fans argue is worse than both of those combined. Lets take a look at who it is and why fans are still upset over it.

While fans typically love the drama of the on-again-off-again couples, sometimes viewers want a sweet, down-to-earth couple who makes you feel good. Henry Burton (Scott Foley) andTeddy Altman(Kim Raver) were once this cute, normal couple.

Well, at least it was as normal as you can get for a Greys Anatomy duo. Henry first came to the hospital as a patient with Von-Hippel-Lindau syndrome without insurance, in need of surgery. Teddy tried to appeal to the hospital, but they offered only a temporary fix. Before he left that day, she suggested they get married so he could be on her insurance.

Henry agreed to the marriage and was able to get his surgery. The pair started as friends (who were married for insurance reasons) but slowly became more. Teddy often would go over to Henrys place after terrible dates and spend excessive time with him.

Fans knew she was falling for Henry before Teddy did. During every one of Henrys surgeries, Teddy became very worried, often acting like a wife. She eventually confessed her love to him, and they became a real married couple.

Of course, right when viewers began to get comfortable with this adorable relationship, Henrys health took a turn for the worst.Cristina Yang(Sandra Oh) operated on a tumor near his heart, but when they opened him up, Richard Webber (James Pickens, Jr.) and Yang found there was too much damage. Henry died on the operating table, and Teddy was devastated right along with the fans at home.

Viewers are convinced that Henry was the best thing to ever happen to Teddy. There are not many fans who like Teddy withOwen Hunt(Kevin McKidd). They continually reminisce about Teddys days with Henry.

Teddy and Henry were such a unique but sensible couple, wrote one Reddit user. I really wish he had stayed alive in the show and moved away somewhere with Teddy. I just never could see Teddy and Owen together, even though they were such good friends.

I always ugly cry when Henry dies, added another Henry fan. I loved this couple so much. They were sweet and normal. They just fit together so well.

Henry was so good for Teddy, reasoned one viewer. I wish they hadnt killed him off. It was also so refreshing to have a character who wasnt a surgeon as a love interest.

Viewers quickly turned a love post about this sweet relationship to a hate post towards the writers of Greys Anatomy.

God, I loved Teddy and Henry, added a Redditor. [They are] still my favorite doctor/patient love story. It was believable. They didnt rush into anything. They met and Teddy offered to marry him so that he could use her insurance. Then they became friends, and then slowly fell in love with each other.

His death hit me harder than Dennys, the Redditor continued. Kims acting was so on point back then, but it has just felt flat in these last two seasons. Teddys speech in season 15, about how Owen is the only one who has ever made her feel rage, is so insulting to Henrys memory.

I dont get it, pondered another fan about the writing comment. Krista was showrunner from season 14 on, and in season 14, the show remembers how much Teddy loved Henry and was furious with Owen.

But then in season 15, they try to chalk it up to her being scared, she continues. If they insist on making Towen a thing, then make it believable. Make us believe that Teddy fell out of love with Owen, and then back in love. Not make it seem like she never moved on.

Fans will continue to debate which death on Greys Anatomy was the most tragic. For now, lets agree on poor Henry. Find out who else is on the operating table when Greys Anatomy returns from winter break on Jan. 23, 2020.

Read more from the original source:
'Grey's Anatomy': Fans Are Still Furious over the Death of This One CharacterThey Claim It Was Worse Than Losing McDreamy - Showbiz Cheat Sheet

Grey’s Anatomy: Why did Patrick Dempsey leave the series? – Express

Dempsey played the role of Derek from the shows inception in 2005 until 2015, after starring in 11 seasons of the medical drama.

He left the show to focus on his family and his passion for auto-racing.

Speaking to People, Dempsey explained leaving Greys Anatomy was simply the end of a chapter.

He said: Im very grateful for Greys Anatomy. Its given me the opportunity to do everything. But at the same time, there was a cost.

I think after a certain period of time, no matter how much money you make, you want control out of your own schedule.

See the article here:
Grey's Anatomy: Why did Patrick Dempsey leave the series? - Express

Fossils Suggest the Egg Came Before the Chicken – Technology Networks

A new study by an international team of researchers, led by scientists from the University of Bristol and Nanjing Institute of Geology and Palaeontology, has discovered that animal-like embryos evolved long before the first animals appear in the fossil record.

Animals evolved from single-celled ancestors, before diversifying into 30 or 40 distinct anatomical designs. When and how animal ancestors made the transition from single-celled microbes to complex multicellular organisms has been the focus of intense debate.

Until now, this question could only be addressed by studying living animals and their relatives, but now the research team has found evidence that a key step in this major evolutionary transition occurred long before complex animals appear in the fossil record, in the fossilized embryos that resemble multicellular stages in the life cycle of single-celled relatives of animals.

The team discovered the fossils named Caveasphaera in 609 million-year old rocks in the Guizhou Province of South China. Individual Caveasphaera fossils are only about half a millimeter in diameter, but X-ray microscopy revealed that they were preserved all the way down to their component cells.

Kelly Vargas, from the University of Bristols School of Earth Sciences, said: X-Ray tomographic microscopy works like a medical CT scanner, but allows us to see features that are less than a thousandth of a millimeter in size. We were able to sort the fossils into growth stages, reconstructing the embryology of Caveasphaera.

Co-author Zongjun Yin, from Nanjing Institute of Geology and Palaeontology in China, added: Our results show that Caveasphaera sorted its cells during embryo development, in just the same way as living animals, including humans, but we have no evidence that these embryos developed into more complex organisms.

Dr John Cunningham, another co-author, said: Caveasphaera had a life cycle like the close living relatives of animals, which alternate between single-celled and multicellular stages. However, Caveasphaera goes one step further, reorganizing those cells during embryology.

Co-author Stefan Bengtson, from the Swedish Museum of Natural History, said Caveasphaera is the earliest evidence of this most important step in the evolution of animals, which allowed them to develop distinct tissue layers and organs.

Maoyan Zhu, from Nanjing Institute of Geology and Palaeontology, said he is not totally convinced that Caveasphaera is an animal. He added: Caveasphaera looks a lot like the embryos of some starfish and corals we dont find the adult stages simply because they are harder to fossilize.

Co-author Dr Federica Marone from the Paul Scherrer Institute in Switzerland said, This study shows the amazing detail that can be preserved in the fossil record but also the power of X-ray microscopes in uncovering secrets preserved in stone without destroying the fossils.

Co-author Professor Philip Donoghue, also from the University of Bristols School of Earth Sciences, said Caveasphaera shows features that look both like microbial relatives of animals and early embryo stages of primitive animals. Were still searching for more fossils that may help us to decide.

Either way, fossils of Caveasphaera tell us that animal-like embryonic development evolved long before the oldest definitive animals appear in the fossil record.

Reference

Yin et al. (2019) The Early Ediacaran Caveasphaera Foreshadows the Evolutionary Origin of Animal-like Embryology. Current Biology. DOI: https://doi.org/10.1016/j.cub.2019.10.057

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read the original:
Fossils Suggest the Egg Came Before the Chicken - Technology Networks

Cleanroom technology for the IVF industry – Cleanroom Technology

3-Dec-2019

Design and Build | Pharmaceuticals

In vitro fertilisation is a process that mimics nature and as such, the industry requires state-of-the-art facilities to control environmental conditions and prevent contamination of the product. Giles Palmer explains

From its humble beginnings in a small cottage hospital in Oldham (UK) to its acceptance in mainstream medicine and everyday life, the in vitro fertilisation (IVF) industry has evolved continuously, and is increasingly applicable not only with the treatment of a growing variety of fertility issues but also with challenges of todays society and lifestyle choices.

Globally, infertility affects seven million people: one in six couples have a problem in conceiving. Last year we celebrated the 40th anniversary of the first test-tube baby, Louise Brown, and in doing so the birth of clinical embryology as a profession.

Over the years, IVF success rates have increased. The introduction of hormonal stimulation produced more oocytes than the early natural cycle attempts leading to a more streamlined and controlled treatment cycle leading to a better choice of embryos to transfer, and the need to cryopreserve remaining embryos.

Originally designed for patients with tubal damagewhen the oocyte could not journey from the oviduct to the uterus to implantthe application of this science has been developed to include all forms of infertility, from hormonal disorders to severe male infertility. The shift has seen the opening of new possibilities that have been both morally, spiritual and socially questioned, such as the use of donor sperm and oocytes, sex selection, genetic screening and posthumous use.

These processes are manual manipulations in laminar flow hood with heated work surfaces, cultured in special low volume incubators

Embryologists working in the lab mimic nature, closely maintaining optimum conditions of temperature, pH and osmolarity; monitoring the development of embryos, and selecting the best embryo for transfer. These processes are manual manipulations in laminar flow hood with heated work surfaces, cultured in special low volume incubators.

Culturing outside the body close to physiological conditions has paved the way for new techniques, such as intracytoplasmic sperm injection (ICSI) and preimplantation diagnosis via embryo biopsy coupled with the ever-evolving science of molecular genetics.

Recent advances in cryobiology have also meant that frozen embryos have now succeeded in producing a viable pregnancy as fresh embryos (Thomson, 2019).

Embryos are routinely cultured now to five- or six-day post insemination before being transferred to the intended mother when the embryo has reached the blastocyst stage. This ready-to-implant embryonic stage (previously difficult to achieve with suboptimal culture media) now has a success rate of 54%, according to London Womens Clinic data.

Giles Palmer, Senior Embryologist

The IVF lab is almost always adjacent to an operating theatre where procedures such as egg collection (by follicle aspiration) under sedation and embryo transfer are performed. The eggs and embryos are transferred hand-to-hand, literally, by a hatch (a passthrough you might say in the cleanroom industry) that must remain open for lengths of time up to 30 minutes.

Positive pressure and HEPA filters are commonplace in IVF laboratories, but industry standards are somewhat elusive: there is no consensus on what constitutes an IVF laboratory, and guidelines may differ greatly from country to country.

Only about 15% of IVF clinics are housed within a hospital, and currently may be designed within a medical centre, doctors offices and general buildings.

The IVF process also requires auxiliary rooms. An andrology laboratory (preferably in a separate room but not globally mandatory) is used to process the non-aseptic semen. A cryobiology room is then used to store the frozen samples. Plus, a medical gas room is also required.

Apart from gases used by the anaesthetists, mixtures of medical-grade gasses are required to produce the correct environment within the incubators for the developing embryo; typically 6% CO2 with low O2 tension.

The IVF industry might not manufacture a product, as many industries using cleanrooms, but it seems appropriate to measure success by an endpoint of the birth of a healthy child. Development and normal growth, however, can be limited in adverse air conditions. The entire IVF process is governed by the biology of sperm, egg and embryo, and we must optimise conditions to protect the product against exposure to adverse external factors. The problem lies in the lack of agreement of these conditions.

The human embryo is sensitive to light, temperature and other environmental conditions. Pollutants can settle on workspaces, and although embryos bathed in their culture media overlaid with a layer of light paraffin oil, attention has to be paid to the risk of toxins infiltrating the barrier because embryos lack an immune system to stave off harmful environmental contaminants.

It should be noted that disposables and new equipment can introduce hazards in the laboratory, too

Urban air can contain high levels of pollutants, such as carbon monoxide, nitrous oxide, sulphur dioxide and heavy metals. Indoor construction materials, such as MDF, PVC flooring, paints and adhesives, constitute the major source of volatile organic compounds (VOCs).

Once only anecdotal in the early days of IVF, studies emerged, showing the negative effect of poor air quality and ultimately, pregnancy outcome (Cohen 1997, Hall 1998, Mayer 1999, Boone 1999). It was shown that compressed gases that fed the incubators had high levels of VOCs (namely benzene, isopropanol and pentane) and it was not uncommon for the laboratory environment to have higher VOC concentrations than indoor air.

Particle monitors and VOC counters have also emerged in the IVF marketplace

The industry took notice and has produced ingenious ways to protect the embryos, from closed laminar flow hoods to improvements to filters systems with in-line gas filters and standalone portable air filtration units. Particle monitors and VOC counters have also emerged in the IVF marketplace (Forman, 2004).

It should be noted that disposables and new equipment can introduce hazards in the laboratory, too. Sterile plastic test tubes and dishes in packages need off-gassing. The polystyrene-based plastics can emit styrene (Sing, 2015), and it is good practice to open the consumables well before use and leave in a laminar flow hood. New equipment must also be burnt in (to release residual VOCs from the manufacturing process) in a separate room before use.

While health and safety authorities have safe limits for VOC exposure for humans, there is nothing documented for developing embryos. Industry guidelines were (and still are) vague, but both the European Society of Human Reproduction and Embryology and the American Society for Reproductive Medicine recognise air quality is a key factor to success (ASRM 2014, ESHRE 2004) yet without specific details.

In 2004, the IVF landscape changed in Europe with the announcement of the European Union Tissue and Cell Directive, which specified precise quality and safety requirements for the donations, procurement, testing coding and storing. A key point in this policy was clean air (EUCTD, 2004). It was meant to bring cell and tissue use on par with blood and organ handling.

Like this story? Subscribe to Cleanroom Technology magazine for incisive analysis of the latest news and developments in hi-tech industries manufacturing in controlled environments.

The inclusion of the IVF was both unexpected and fiercely debated (Mortimer 2005, Saunders and Pope 2005) because the original specifications would have been detrimental to in vitro embryo development.

The Directive stated: Where tissues or cells are exposed to the environment (...) an air quality of Grade A, as defined in the current European Guide to Good Manufacturing Practice, is required. The background must be demonstrated to guarantee the maintenance of Grade A in the tissue/cell manipulation while in use and unmanned. The document highlighted areas of improvements; there was little or no air management before this draft.

Where tissues or cells are exposed to the environment (...) an air quality of Grade A, as defined in the current European Guide to Good Manufacturing Practice, is required

It was argued that risk of infection is low and that the product cannot be sterilised. Equally, the cooling effects of maintaining airflow of a Grade A environment would have been detrimental to embryo culture and introduce vibrations not conducive to fine accurate manipulation needed in many techniques.

A second draft of the Directive stated a less stringent environment if Grade A was either detrimental or technically impossible, but did not define a level of air quality other than close to A.

In the UK, the Human Fertilisation and Embryology Authority (HFEA), a government watchdog, supported a Grade C working environment with a background of Grade D. From 2007, all manipulations must be within a Class II laminar flow hood. This regulation meant IVF labs at the very least had to make some adjustments to facilities and standard operating procedure. In the design of a laboratory, great care should be placed on location and adjacent rooms, so to avoid proximity to laundry, canteen or pathology labs emitting possible air contaminants. In a hospital environment, however, limited available space is always a problem.

The same deal of attention should be paid during and after laboratory renovation or build. The wrong materials can be the difference between a triumphant inauguration with great IVF success rates or failure with long-lasting effects.

Construction should involve using furniture free of VOCs, preferably stainless steel and low VOC materials and adhesives.

Lab improvements can help increase IVF success by implementing cleanroom standards

In a study following the VOC measurements during a renovation of a laboratory, I was able to show key VOC emissions, such as ethyl alcohol, acetone, hexane and toluene, at various point of construction phases, and ways to alleviate and eliminate the VOCs upon completion of the work (Palmer, 2010). This may be common knowledge to the cleanroom aficionados, but was something quite new a decade or so ago.

Other papers on air quality improvements followed, illustrating how lab improvements can help increase IVF success by implementing cleanroom standards.

Heitmann et al. in 2015, for example, described how a former lab with an unreliable HVAC system was transformed. The project used the strategy of pre-filter, photocatalytic irradiation and chemical filtration, by means of activated carbon, potassium permanganate, and finally HEPA filters. Implantation rates were drastically increased, and clinical pregnancy rate increased by 10%.

Still, as IVF resides predominately in the private healthcare sector, a great variety of different types of facilities exist, from renovated listed buildings of grandeur to purpose-built installations.

There was a clear need for clarity within the existing guidelines on optimal laboratory conditions, but in a recently published article, a survey of 36 clinics using an IVF quality control app globally, little conformity could be found (Palmer, 2019).

Laboratory temperatures varied from 17oC to 35oC, and humidity from 5% to 80%; only four laboratories measured air quality; and only two measured VOCs.

The implementation of stricter guidelines is not always welcome. The mere mention of my talk on this subject at Cleanzone Middle East on social media raised a quiet storm doubting the merits of cleanroom technologies. Those raising an eyebrow pointed to costs, increase in staff required and questioned the necessity. Needless to say, the feedback was from old school scientists who had clearly not read or approved of the recent Cairo consensus published in 2018.

The Cairo meeting of experts was set out in the wake of growing evidence for recommending technical and operational requirements, control of particulates, aspirational benchmarks, and help in laboratory commissioning in the future.

The mere mention of my talk on this subject at Cleanzone Middle East on social media raised a quiet storm doubting the merits of cleanroom technologies

The meeting listed the most common agents of contamination and compared a large number of older facilities with laboratories using cleanroom concepts:

In all, there were over 50 consensus points, and it was concluded that cleanroom design should be implemented in any new IVF laboratory builds.

The global fertility rate continues to decline. Main culprits of this trend are the increase in obesity, environmental factors and lifestyle as well as psychographic changes.

Based on 2019 figures, there are over 3,000 clinics worldwide, and the need for IVF is ever-growing. In the US, 1.5% of all children born are a result of assisted reproduction, while the number is 4% in Australia and Israel, and in Denmark 6.4%.

Several economic sources have valued the market to be approximately US$16 billion, with a compound annual growth rate (CAGR) of almost 10%. If this growth holds strong for the next five years, it would mean an industry worth nearly $40 billion by 2025.

Growth is similar in all areas of the globe and large corporations, backed by venture capitalists, are consolidating chains of clinics. Once a reserve of private consultants or small groups of doctors, IVF clinics have now gone big, resulting in chains of IVF clinics.

The success of freezing produces an ever-increasing inventory of cryo-stored embryos, and estimates from IVF research group TMR forecast 21 million people will have stored samples by 2025

The IVF industry has to invest in new facilities equipped with state-of-the-art technology to keep up with this demand and produce high and reproducible standards. The success of freezing produces an ever-increasing inventory of cryo-stored embryos, and estimates from IVF research group TMR forecast 21 million people will have stored samples by 2025. This is a huge capacity that will need significant infrastructure to back it up.

Driven by technological advances, especially in the field of fertility preservation, we will see IVF clinics even more widespread and frequently used than they are today.

Consulting on various projects, in the UK and abroad, I have seen a huge lack in understanding of what is required to construct and maintain a successful IVF facility. I welcome the introduction of cleanroom companies into the IVF industry, as many aspects of your work and products are applicable to our industry today.

The modular cleanroom initiatives, such as the Shellbe system, are particularly appealing for their capacity to produce a zero VOC laboratory customised to the clients needs.

I welcome the introduction of cleanroom companies into the IVF industry, as many aspects of your work and products are applicable to our industry today

Fickle and demanding, we embryologists may be about the conditions and the design of the IVF clinic, but I am often hampered by lack of local expertise (or material) in various places of the world. As real estate costs and availability become so prohibitive in many cities, the portable, adaptable modular lab can be designed, shipped and constructed like Lego and fit suitably in spaces that were previously unutilised.

With so much evidence and interest in our field, now is the time for the IVF industry to enter the biotechnology arena and be ready for cleanroom technology.

N.B. This article is featured in the December 2019 issue of Cleanroom Technology. Subscribe today and get your print copy!

The latest digital edition is available online.

See original here:
Cleanroom technology for the IVF industry - Cleanroom Technology

Letter to the Editor: Arguments for equal and human rights must include the unborn – Tulsa World

As a future social worker, I am fascinated that unborn humans are often left out of the rhetoric for equal and basic human rights.

The following statements are held to be true by all social workers who adhere to the National Association of Social Workers Code of Ethics:

Social workers strive to help meet the basic human needs of all people, and every human life has inherent dignity and worth.

Isn't the most basic, fundamental need the right to life?

Furthermore, the first principle of a widely accepted social work ethics guide states the social workers first priority is the protection of human life, which applies to all persons, both the life of a client and the lives of all others.

The science of embryology shows the unborn child is a distinct human life from the moment of fertilization. If the social worker recognizes that every human life has inherent worth and basic rights and has pledged to defend those rights, what is the social worker's responsibility to the unborn population?

One may respond by saying that social workers must respect the self-determination of their clients.

However, according to the NASW Ethical Standards, "Social workers may limit clients' rights to self-determination when . . . (their) actions pose a serious, foreseeable, and imminent risk to themselves or others."

What if ones actions are posing a death risk to the human in their womb?

When considering the defense of vulnerable populations, lets remember the unborn.

Originally posted here:
Letter to the Editor: Arguments for equal and human rights must include the unborn - Tulsa World

Numero quattro: Immunology experts at deal-focused IFM line up $55.5M for the next leg of their drug exploration journey – Endpoints News

Its pipeline priming time at IFM Therapeutics. And they have the money to get the job done.

The immunology experts at the discovery outfit have lined up $55.5 million in new venture backing from an expanded syndicate still including their big believers at Atlas. And its not hard to figure out the motivation.

Gary Glick, whos moving from CEO to executive chairman on this round, and his team have lined up a slate of deals for their early-stage work.

Just 2 months ago Novartiss NIBR stepped up with an $840 million buyout option tied to research funding for therapeutics that fire up the STING pathway. And theyve reaped more than $600 million in cash from Bristol-Myers and Novartis on both sides of NLRP3, tamping down as well as triggering that pathway, in addition to STING.

The financing will have a goal of graduating 2 programs into subsidiaries, says Martin Seidel, a NIBR vet whos now moving up to the CEO post after running research for IFM over the last couple of years.

Now comes their third subsidiary, IFM Quattro, as the crew also starts their own incubator to play with some new ideas in the field.

Theyre sticking to their area of expertise in the innate immune system, looking for new ways that work in fighting cancer as well as new anti-inflammatories. What exactly is on the horizon is a topic they arent ready to discuss with Endpoints News, but there are a variety of possibilities. Just a couple of weeks ago a group of their scientists and collaborators published new work on the role the inflammasome plays in tau pathology a possible new approach to Alzheimers, where nothing has worked so far.

So the plan at a high level is to continue to execute on the strategy: Take target specific programs into subsidiaries and then hunt up partners around the IND stage, says Lina Gugucheva, the BD chief at IFM. The new venture round will be enough to fuel the company of 35 staffers for the next 3 years or so as it sets up the new subsidiaries and starts to look to execute new deals.

With their track record, backers have good reason to believe that IFM has decent odds of paying off again with a solid multiple in a relatively short span of time. As a result, says Glick, there was plenty of interest from new investors, and they opted to let Omega Funds into the small syndicate, alongside Atlas and Abingworth. Omegas Paulina Hill joins Jean-Francois Formela at Atlas and Shelley Chu from Abingworth on the board.

So whats with the Italian numbering system at IFM? Glick says it was inspired by a traditional 12 course Italian meal. And that leaves IFM preparing the main course.

Social image: Martin Seidel, Gary Glick, Lina Gugucheva

Read more:
Numero quattro: Immunology experts at deal-focused IFM line up $55.5M for the next leg of their drug exploration journey - Endpoints News

Winter allergies and your Christmas tree – KJCT8.com

GRAND JUNCTION, Colo. (KJCT) - If youre finding yourself sniffling this time of year, youre not alone.

According to Mayo Clinic, more than 16 million Americans suffer from Winter Allergies. This irritation can be caused by regular indoor offenders but your holiday centerpiece might also be to blame. Its often not the Christmas trees themselves but the mold that grows on it.

If you really get your head in there and inhale a lot of that particulate matter from the tree, that can really put people into a few days of sinus congestion, sometimes even lead to sinusitis, says Allergy and Immunology Specialist David Scott, M.D.

Expert recommend keeping your tree in a well-ventilated area.

Read the original here:
Winter allergies and your Christmas tree - KJCT8.com

UC Merced Aims to Draw 1,000 Donors in a Day with ‘Give Tue UC Merced’ Campaign | Newsroom – UC Merced University News

By Michelle Morgante, UC Merced

The annual Give Tue UC Merced campaign takes place on Tuesday, Dec. 3.

Jose Nava-Mejia hopes to work in renewable energy after he graduates from UC Merced. That means every moment spent on his environmental energy courses is a moment invested in the planets future.

Kelsey Duggin hopes to use her microbiology and immunology studies to become a virologist and work with stem cells. Vania Huaranga plans to become a neuropsychologist.

The three are among the scores of UC Merced undergraduates whose studies are backed by the Build the Future Scholarship Fund, which is supported by donations collected during Give Tue UC Merced.

The annual day of giving campaign takes place Tuesday, Dec. 3. During the 24 hours of worldwide Giving Tuesday, UC Merced has set a goal of drawing gifts from 1,000 donors.

Donations designated for the Build the Future Scholarship Fund will be matched 3-to-1 by Foster Poultry Farms, quadrupling the impact of every dollar.

In addition, donors can support UC Merceds Graduate Student Fellowship Fund. The first 100 donations to the fund will be amplified by a matching donation that will provide up to $1,000 from longtime campus friends Dr. Robert Bernstein and Dr. Jane Binger. Vice Provost and Graduate Dean Marjorie Zatz is offering a similar match.

This years Give Tue UC Merced marks the sixth year of the campaign.

Support from the gifts made during Give Tue UC Merced transforms the lives of our students, their families and their communities, interim Chancellor Nathan Brostrom said. Every donation helps us build a better future by supporting the education of the next generation of world-class researchers.

Nava-Mejia, a 19-year-old first-generation student from Merced, said the Build the Future Scholarship allows him to devote more time to his studies.

It means a lot because I can focus on my education, he said. With the scholarship, I can pay for my books and transportation costs. It also lifts a burden off my parents.

UC Merced is a national leader in student outcomes and social mobility, with nine out of 10 students receiving some form of financial assistance. Such financial support was one of the main reasons Duggin decided to enroll.

The support from the Build the Future Scholarship has provided me with the ability to pay for all of the basic necessities, said the second-year student from La Crescenta. It gave me reassurance that hard-working students are rewarded and it motivates me to continue to prioritize my studies.

For Huaranga, a first-year psychology major from Antioch, the Build the Future Scholarship not only provides financial backing, it helps her feel supported as she transitions into college life.

"As a first-generation student, college tuition can be very costly for our families," she said. The Build the Future Scholarship has been very significant to me for many reasons but my main reason is that it gave me a sense that there are people out there who support students. This made me feel that I am not alone and that there are people who believe in me.

"Support from the gifts made during Give Tue UC Merced transforms the lives of our students, their families and their communities.

Last year, the Give Tue UC Merced campaign raised more than $170,000, bringing the total collected over the past five years to more than $1.5 million.

Currently, 144 students are receiving support from the Build the Future Scholarship. And thanks to the generosity of Foster Poultry Farms, there will be a 3-to-1 match on gifts made to the Build the Future Scholarship Fund, up to a total of $100,000 during Give Tue UC Merced.

Online gifts can be directed to givetue.ucmerced.edu ; Donations also will be collected at locations across campus on Tuesday, Dec. 3.

Numerous events will be held on campus throughout the day to raise awareness of Give Tue UC Merced and support a culture of giving back. Housing and Residence Life is organizing a Dollars for Scholars carnival event, including a chance for donors to toss pies at resident assistants and a holiday social featuring an ugly sweater contest. The events are open to all students and a $1 donation is encouraged.

The Graduate Division will offer coffee and churros to donors Tuesday afternoon.

Last year marked the second year in which the campus met its 1,000-donor goal on Give Tue UC Merced. Those donors included nearly 500 students, underscoring a growing tradition of giving among Bobcats.

Huaranga said receiving support from the Build the Future Scholarship has inspired her to want to, in the future, give scholarships that will help students from her hometown attend UC Merced.

Duggin said she also hopes to contribute to the university.

I hope to eventually be able to give back to UC Merced, specifically to benefit the students. I want the future generations to have access to a great education without worrying about finances, Duggin said. Give Tue UC Merced is a great event that allows donors to support the school and the students. Thank you to the donors who invest in the students at UC Merced it really makes a difference.

Continue reading here:
UC Merced Aims to Draw 1,000 Donors in a Day with 'Give Tue UC Merced' Campaign | Newsroom - UC Merced University News